Bayer Aspirin MI, Stroke Prevention Comparative Claims Targeted By FDA
This article was originally published in The Tan Sheet
Executive Summary
Marketing claims comparing the use of Bayer Aspirin for heart attack and stroke prevention to the prescription antiplatelet drug Plavix are targeted by FDA in a Dec. 17 warning letter to Bayer. The agency objects to several claims in a promotional brochure for medical professionals and a "Dear Doctor" letter circulated by the firm in early 1998.